ArticlePatient preference and adherence2026
A Quantitative Discrete Choice Experiment Survey-Based Study of Preferences for a Hypothetical Long-Acting Injectable Antipsychotic Administered Once Every 2 Months Among People Living with Schizophrenia.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This quantitative preference study aimed to quantify the strength of preferences for a hypothetical once-every-2-months long-acting injectable (LAI) vs an oral medication or once-monthly LAI, to identify the factors that drive preference for a once-every-2-months LAI and to evaluate these preferences in relation to the current treatment in schizophrenia. Methods: An online survey that included a discrete choice experiment (DCE) component was used to quantify the preferences of adults living with schizophrenia who were receiving treatment with an oral antipsychotic or a once-monthly LAI from five countries across North America and Europe. The survey included questions about the respondent and their attitudes towards schizophrenia and treatment, including their views on a hypothetical LAI taken once every 2 months. The DCE component was used to determine preference weights for levels of the following treatment attributes: mode and frequency of administration, flexibility of administration, psychiatric hospital admission, symptom improvement, social functioning, feelings of sedation, and overall weight gain. Results: In total, 212 people living with schizophrenia completed the survey, of whom 66.5% were "very satisfied" or "satisfied" with their current treatment. A greater proportion of people living with schizophrenia currently receiving a once-monthly LAI (67.0%) were "very likely" or "likely" to try a hypothetical once-every-2-months LAI than those receiving oral treatment (46.2%). The most common motivation for trying a hypothetical once-every-2-months LAI was to not have to think of taking the medicine as often (43.6%), while the most common barrier was a fear of needles (30.4%). Results from the DCE indicated that symptomatic improvement and a reduced risk of hospital admission were among most important treatment attributes for acceptance. Conclusions: Most people living with schizophrenia were open to the idea of trying a hypothetical once-every-2-months LAI treatment for schizophrenia, particularly those who were currently receiving a once-monthly LAI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.